The quality of pharmaceuticals has been a concern of WHO since its inception.
Owing to the nature of these products, this concern includes the quality of the
starting materials, i.e. active pharmaceutical ingredients (APIs) and
excipients, used for the production of pharmaceuticals.
This guidance text, in combination with other recommendations and guidelines
issued by WHO, will be an important step towards ensuring the quality and
traceability of pharmaceutical starting materials and in assigning the
responsibility for specifications within the processes of manufacture, storage
and distribution of pharmaceutical starting materials. Member States are urged to establish and maintain a legal framework and
regulatory approach to ensure that good practices for the trade and distribution
of pharmaceutical starting materials are followed.
Member States can establish appropriate regulatory control by implementing
one or both of the following approaches: licensing of suppliers, including traders, brokers and distributors; and/ora
registration or notification system of suppliers, including traders, brokers and
distributors.A variety of WHO guidelines ready for use and inclusion into
national legislation are available. Their implementation will be crucial
throughout the process towards ensuring the availability and use of quality
pharmaceutical starting materials in the manufacture of medicines.
Where a licensing system already exists, inspections should be performed by
persons from the competent national or regional statutory authority to assess
compliance with good trade and distribution practices (GTDP). Where a
notification or registration system is to be implemented, voluntary inspections
may be performed before certification for compliance with GTDP.
The use of the new certification scheme is based on the existence of a
quality assurance system for the production of starting materials. All parties
involved in the trade and distribution of pharmaceutical starting materials are
strongly encouraged to comply with the GTDP. Manufacturers of pharmaceutical
products should encourage and assist their suppliers to use good storage
practice (GSP), GTDP and the relevant parts of good manufacturing practice
Trade associations are also encouraged to incorporate these principles into
their own codes of practice to be followed by their members.
Another recommendation is the development of a global database listing
information on suppliers (e.g. names and addresses) to enable customers to
verify supplier information. A global database could later be established to
assist in the attempt to address the problem of counterfeiting of pharmaceutical
Training workshops and conferences on GTDP should be planned to promote these
The establishment of model certificates for GSP and GTDP should be envisaged.
National legislation should ensure that penalties can be enforced when
persons or suppliers are found to be in violation of legislation. An alert
system should be established by the competent authority to prevent trade in
non-conforming materials that could put patients at risk. WHO should be informed
of such instances so that this information can be made available to other
national or regional authorities for action as necessary.